The Food and Drug Administration (FDA) released new guidance on
MPX to help increase availability of tests and expand available
testing capabilities in healthcare settings, reference
laboratories, and commercial laboratories. The guidance follows
a declaration by the Secretary of the Department of Health and
Human Services justifying the emergency use authorization
(EUA) of in vitro diagnostics for detection and/or diagnosis of
the MPX virus or non-variola orthopoxviruses.
CSAC will continue to work with local public health officials to
seek adequate resources to support prevention and mitigation
efforts. Those wanting to learn more about MPX transmission,
symptoms, and prevention, as well as data on the number of
reported cases, including demographic detail, can visit the
California
Department of Public Health’s webpage.
